Musa Yilmaz, MD, on FLT3-ITD–Mutated AML: Findings on Quizartinib With Decitabine and Venetoclax
2021 ASH Annual Meeting & Exposition
Musa Yilmaz, MD, of The University of Texas MD Anderson Cancer Center, discusses study results suggesting that quizartinib with decitabine and venetoclax is active in patients with FLT3-ITD–mutated acute myeloid leukemia and that RAS/MAPK mutations continue to drive primary and secondary resistance (Abstract 370).
The ASCO Post Staff
Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, discusses findings from her analysis of the International Blood and Marrow Transplant Research Database, which led to the recent FDA approval of abatacept for the prevention of acute graft-vs-host disease (GVHD) in adult and pediatric patients. The data suggest improved overall survival with the immunosuppressant abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA–matched unrelated allogeneic hematopoietic stem cell transplantation (Abstract 3912).
The ASCO Post Staff
Talha Badar, MD, of the Mayo Clinic, discusses the near-universal poor outcomes for patients with TP53-mutated acute myeloid leukemia and the findings that show allogeneic stem cell transplantation appears to improve the long-term survival in a subset of these patients. Effective therapies may successfully bridge patients to transplant and prolong survival for those who are transplant-ineligible (Abstract 797).
The ASCO Post Staff
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses phase II results from a multicenter study that showed the efficacy of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in younger, fit patients with chronic lymphocytic leukemia who desire the possibility of a functional cure with time-limited therapy (Abstract 640).
The ASCO Post Staff
Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a retrospective study at an academic institution, which showed there was no statistically significant difference in overall survival between induction with CPX-351 and venetoclax/azacitidine for adults with acute myeloid leukemia. Prospective studies to confirm similar effectiveness with careful attention to side effects, quality of life, and impact on transplant outcomes may help clinicians decide between these therapies (Abstract 795).
The ASCO Post Staff
Sangeetha Venugopal, MD, of The University of Texas MD Anderson Cancer Center, discusses a retrospective analysis of 562 patients with treated secondary acute myeloid leukemia and prior exposure to hypomethylating agents (HMAs). The results showed that an HMA plus venetoclax yielded significantly higher overall response rates and improved overall survival compared with intensive chemotherapy or low-intensity chemotherapy, particularly in patients 60 years or older who had a karyotype without adverse risk (Abstract 794).